Skip to main content
Clinical Trials/NCT06412419
NCT06412419
Not yet recruiting
Not Applicable

Based on Multimodal Endoscopy and Weakly Supervised Deep Learning-Early Esophageal Squamous Cell Carcinoma Infiltration Depth Precise Prediction Study

Changhai Hospital1 site in 1 country450 target enrollmentMay 15, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Esophageal Neoplasms Malignant
Sponsor
Changhai Hospital
Enrollment
450
Locations
1
Primary Endpoint
Performance of models to diagnose low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and superficial esophageal squamous carcinoma
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

The objective of this project is to pioneer a novel protocol for the adjunctive screening of early-stage esophageal cancer and its precancerous lesions. The anticipated outcomes include simplifying the training process for users, shortening the duration of examinations, and achieving a more precise assessment of the extent of esophageal cancer invasion than what is currently possible with ultrasound technology. This research endeavors to harness the synergy of endoscopic ultrasound (EUS) and Magnifying endoscopy, augmented by the pattern recognition and correlation capabilities of artificial intelligence (AI), to detect early esophageal squamous cell carcinoma and its invasiveness, along with high-grade intraepithelial neoplasia. The overarching goal is to ascertain the potential and significance of this approach in the early detection of esophageal cancer.

The project's primary goals are to develop three distinct AI-assisted diagnostic systems:

An AI-driven electronic endoscopic diagnosis system designed to autonomously identify lesions.

An AI-based EUS diagnostic system capable of automatically delineating the affected areas.

A multimodal diagnostic framework that integrates electronic endoscopy with EUS to enhance diagnostic accuracy and efficiency.

Detailed Description

The study was executed in two distinct phases. The initial phase, designated as the modeling phase (Phase 1), involved a retrospective analysis of eligible subjects from a consortium of medical institutions, including the First Affiliated Hospital of Naval Medical University, West China Hospital of Sichuan University, Provincial Hospital Affiliated to Shandong First Medical University, the First Affiliated Hospital of Soochow University, the First Affiliated Hospital of Henan University of Science and Technology, and the First Affiliated Hospital of Shihezi University, all selected prior to January 1, 2024. The second phase, known as the real-world evaluation phase (Phase 2), prospectively enrolled consecutive patients who were scheduled to undergo magnometric endoscopy and EUS at the aforementioned hospitals between April 2024 and June 2024.

Registry
clinicaltrials.gov
Start Date
May 15, 2024
End Date
October 30, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients requiring magnifying endoscopy and endoscopic ultrasonography. Individuals of either sex, aged 18 years or older.

Exclusion Criteria

  • Inability to complete esophageal electronic endoscopy. Absence of biopsy or surgery, resulting in unobtainable pathological results. Patients who have undergone endoscopic lesion destruction or piecemeal resection, preventing the acquisition of an en bloc resection sample.
  • Patients with significant endoscopic, imaging, or pathological evidence of advanced esophageal cancer.
  • Patients presenting with marked esophageal stenosis or dilatation. Individuals with a history of other malignancies. Patients who have received neoadjuvant radiotherapy. Patients who declined to participate in the study and did not provide informed consent.

Outcomes

Primary Outcomes

Performance of models to diagnose low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and superficial esophageal squamous carcinoma

Time Frame: 2024.04.01-2024.10.30

Endoscopic Submucosal Dissection (ESD) serving as the gold standard. Computation of sensitivity and specificity involves the use of four fundamental metrics: true positive (TP), true negative (TN), false negative (FN), and false positive (FP). Subsequently, the Area Under the Curve (AUC) is utilized to assess the diagnostic efficacy of the model.

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Parkinson's Pen ProjectParkinson's diseaseNervous System Diseases
ISRCTN26683545orthumbria Healthcare NHS Foundation Trust202
Recruiting
Not Applicable
Novel Strategy for Early Detection of Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaEsophageal Squamous Dysplasia
NCT05028725University of California, San Francisco289
Unknown
Not Applicable
Non-invasive, Wearable Multi-parameter System for the Early Prediction of Cognitive Decline and Dementia in Older AdultsMild Cognitive ImpairmentHealthy Aging
NCT04262674Empa, Swiss Federal Laboratories for Materials Science and Technology82
Active, not recruiting
Phase 1
Advanced imaging for identifying chemotherapy-induced cardiac damage in lymphoma patientsHodgkin and non-Hodgkin lymphomaMedDRA version: 17.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 17.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 17.1Level: HLGTClassification code 10025322Term: Lymphomas non-Hodgkin's unspecified histologySystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 17.1Level: HLGTClassification code 10025321Term: Lymphomas non-Hodgkin's T-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2014-002226-13-DKRigshospitalet100
Recruiting
Not Applicable
AI-enabled Endoscopic Prediction of Post-operative Recurrence in Crohn's DiseaseCrohn Disease
NCT06505304University College Cork225